GTCR Announces Divestiture of Corza Medical's Biosurgery Business Unit to EQT

GTCR, a prominent private equity firm, has signed a definitive agreement to sell Corza Medical's Biosurgery business unit, which includes the TachoSil product portfolio, to EQT for an undisclosed amount. The transaction is anticipated to close in the fourth quarter of 2026, pending customary closing conditions and regulatory approvals. Following the sale, GTCR will retain ownership of Corza Medical's remaining business units, which focus on Wound Closure, Ophthalmology, and Biomedical Textiles.

Corza Medical, established in 2019 through GTCR's Leaders Strategy™ investment approach, has rapidly positioned itself as a key player in the global medical technology sector. The company specializes in innovative surgical solutions, boasting a diverse portfolio that includes industry-leading brands such as Quill® barbed sutures and Blink™ single-use ophthalmic instruments. The sale of the Biosurgery unit marks a strategic move to allow Corza Medical to concentrate on its core business areas while enabling the Biosurgery division to pursue its next growth phase under EQT's stewardship.

The Biosurgery business, particularly known for its TachoSil product, has demonstrated significant potential for expansion. TachoSil is recognized for its clinical value in improving patient outcomes during critical surgical procedures, supported by strong physician preference and extensive clinical evidence. The transaction is expected to enhance the operational capabilities of the Biosurgery unit, allowing for increased investment in growth initiatives and further development of its product offerings.

EQT, a global investment organization managing approximately EUR 269 billion in total assets, aims to leverage its resources to support the growth of Corza's Biosurgery business. The firm has a track record of investing in companies that prioritize sustainable growth and operational excellence, aligning with the strategic objectives of the Biosurgery unit. This partnership is anticipated to strengthen the unit's position as a leading platform in the biosurgery market.

The broader implications of this transaction reflect ongoing trends within the healthcare sector, where consolidation and strategic divestitures are common as companies seek to optimize their portfolios. By allowing Corza Medical to focus on its remaining business units while providing the Biosurgery division with the opportunity for dedicated growth, this deal exemplifies a strategic realignment that could enhance competitive positioning in the evolving medical technology landscape. As the healthcare market continues to adapt, such transactions are likely to play a crucial role in shaping the future of medical device companies.